Revaax Pharmaceuticals, LLC

Eli Lilly and Company

Michael O Chaney

Gary A Koppel

Robin D Cooper

Robert F Bruns, Jr

David C Hunden

Jeffrey J Skelton

The treatment of neurological disorders using cephalosporin sulfoxide-containing and/or cephalosporin sulfone-containing compositions and pharmaceutical compositions including oral dosage forms that include cephalosporin sulfoxide and/or sulfone-containing compositions are described.

Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions

Administration of inhibitors of carboxypeptidase E provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior and enhanced cognition. Certain &bgr;-Lactam antibiotics, most significantly, certain 1-oxa-1-dethia cephems with blood brain barrier transport, exhibit potent therapeutic neurologic activity.

Neurotherapeutic use of carboxypeptidase inhibitors

This invention relates to a combinatorial process for synthesizing a library of azetidinone peptide-like compounds. The compounds are synthesized as mixtures from a common azetidinone intermediate. The compounds are biologically active as inhibitors of the Vasopressin (V1a) receptor.

Growing community of inventors

Carmel, IN, United States of America

Michael O Chaney